[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337063-105":59,"doc-detail-337063-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-novel-regulatory-axis-of-msi2-ago2mir-30a-3p-cgrrf1-drives-cancer-chemoresistance-by-upregulating-the-kraserk-pathway","A novel regulatory axis of MSI2-AGO2/miR-30a-3p-CGRRF1 drives cancer chemoresistance by upregulating the KRAS/ERK pathway","","The KRAS/ERK pathway is central to cancer progression and chemotherapy resistance, yet its upstream control has been insufficiently defined. MSI2 is identified as a promoter of chemotherapy resistance and a new regulator within the miRNA pathway. MSI2 binds mature miRNAs via the “UAG” motif and cooperates with AGO2 to load miR-30a-3p, suppressing CGRRF1. CGRRF1 acts as a ubiquitin E3 ligase for KRAS, driving KRAS ubiquitination and proteasomal degradation, thereby activating KRAS/ERK signaling.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-novel-regulatory-axis-of-msi2-ago2mir-30a-3p-cgrrf1-drives-cancer-chemoresistance-by-upregulating-the-kraserk-pathway/337063/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-novel-regulatory-axis-of-msi2-ago2mir-30a-3p-cgrrf1-drives-cancer-chemoresistance-by-upregulating-the-kraserk-pathway/337063.png","ImageObject",300,407,{"name":92,"@type":93},"Seraphina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does MSI2 play in chemotherapy resistance according to the study?","Question",{"text":112,"@type":113},"MSI2 is identified as a promoter of chemotherapy resistance in cancers by regulating miRNA processing and downstream signaling.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do MSI2 and AGO2 interact with miRNAs in this regulatory axis?",{"text":117,"@type":113},"MSI2 directly binds a mature miRNA class by recognizing the “UAG” motif and interacts with AGO2 to facilitate miR-30a-3p loading onto AGO2.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the proposed mechanism connecting CGRRF1 to KRAS/ERK pathway activation?",{"text":121,"@type":113},"CGRRF1 functions as a ubiquitin E3 ligase for KRAS, mediating KRAS ubiquitination and proteasome degradation, which supports activation of the KRAS/ERK pathway.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337063,1790104387,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","Neoplasia 59 (2025) 101082  \nContents lists available at ScienceDirect  \nNeoplasia  \njournal [homepage:](homepage: www.elsevier.com/locate/neo)[ www.elsevier.com/locate/neo](homepage: www.elsevier.com/locate/neo)  \n| Original Research\u003Cbr>A novel regulatory axis of MSI2-AGO2/miR-30a-3p-CGRRF1 drives cancer chemoresistance by upregulating the KRAS/ERK pathway |  |  | |\n| --- | --- | --- | --- |\n| Runhui Lua,1, Yafan Zhang a,1, Ran Chena,1, Lian Lia,b,1, Caihu Huang a, Zihan Zhou a, Yingting Cao a, Hongyan Lia, Junya Lia, Yixin Zhang a, Yanli Wang a, Jian Huang a, Xian Zhao a, Jing Feng c,*, Jianxiu Yu a,b,*, Chunling Dub,*\u003Cbr>a Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory of Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China\u003Cbr>b Department of Respiratory and Critical Care Medicine, QingPu Branch of Zhongshan Hospital Affiliated To Fudan University, Shanghai 201700, China c Department of Laboratory Medicine,The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China |  |  |  |\n| A R T I C L E I N F O |  | A B S T R A C T |  |\n| Keywords:\u003Cbr>Cancer chemoresistance RNA binding protein MSI2 miRNA\u003Cbr>KRAS\u003Cbr>CGRRF1\u003Cbr>MAPK/ERK |  | The KRAS/ERK pathway is crucial in cancer progression and chemotherapy resistance, yet its upstream regulatory mechanism remains elusive. We identified MSI2 as a new promoter of chemotherapy resistance in cancers. MSI2 directly binds to a specific class of mature miRNAs by recognizing the ’UAG’ motif and interacts with the essential effector AGO2, highlighting MSI2 as a novel regulatory factor within the miRNA pathway. Specifically, MSI2 recruits UAG-miRNA miR-30a-3p to facilitate its loading onto AGO2, efficiently inhibiting the expression of CGRRF1. Further analysis reveals that CGRRF1 functions as a new ubiquitin E3 ligase for KRAS, mediating the ubiquitination and proteasome degradation of KRAS. Consequently, a novel regulatory axis involving MSI2-AGO2/miR-30a-3p-CGRRF1 positively regulates the KRAS/ERK pathway. Remarkably, platinum-based chemotherapy drugs significantly enhance the levels of phosphorylated ERK1/2 (p-ERK1/2) in cancer cells, and the EGFR inhibitor Gefitinib also increases p-ERK1/2 levels in Gefitinib-resistant cancer cells. Combining smallmolecule inhibitors targeting MSI2, such as Ro 08-2750, efficiently alleviated chemoresistance in tumor cells exposed to Platinum and Gefitinib. These findings suggest that MSI2 could be a novel therapeutic target for developing strategies to counteract cancer resistance to treatment. |  |\n\nIntroduction  \nMost malignant cancer patients have no obvious symptoms in the early stages, such as prostate cancer and lung cancer. As cancer progresses, cancer cells gradually migrate and invade, which significantly contributes to the high cancer mortality rates. Chemotherapy remains the primary treatment option for cancer patients due to limited therapeutic alternatives. However, only 10–20 % of patients respond positively to chemotherapy, and chemoresistance often develops within weeks of treatment initiation [1]. Numerous studies have highlighted the upregulation of the MAPK/ERK pathway as a key factor contributing to chemotherapy resistance [2,3]. KRAS serves as the key signaling activator upstream of the MAPK/ERK pathway and is also one of the most well-known oncogenes [4,5]. It ranks among the genes with the highest mutation frequency in clinical tumors [6,7]. Recent studies have  \nrevealed that an increase in intracellular wild-type (WT) KRAS protein levels can also have biological effects, independent of its mutations. This increased KRAS protein activates downstream signaling pathways, thereby accelerating cancer progression [3,8]. It has been reported that LZTR1 as a ligase E3 mediates the ubiquitination and degradation of RAS family proteins, inhibiting MAPK signaling and tumor cell growth [9,10]. Despite","cbCaigkBOQxRwcI5","https://ap.wps.com/l/cbCaigkBOQxRwcI5","pdf",9092330,17,"English","# Introduction","[{\"question\":\"What role does MSI2 play in chemotherapy resistance according to the study?\",\"answer\":\"MSI2 is identified as a promoter of chemotherapy resistance in cancers by regulating miRNA processing and downstream signaling.\"},{\"question\":\"How do MSI2 and AGO2 interact with miRNAs in this regulatory axis?\",\"answer\":\"MSI2 directly binds a mature miRNA class by recognizing the “UAG” motif and interacts with AGO2 to facilitate miR-30a-3p loading onto AGO2.\"},{\"question\":\"What is the proposed mechanism connecting CGRRF1 to KRAS/ERK pathway activation?\",\"answer\":\"CGRRF1 functions as a ubiquitin E3 ligase for KRAS, mediating KRAS ubiquitination and proteasome degradation, which supports activation of the KRAS/ERK pathway.\"}]","A novel regulatory axis of MSI2-AGO2/miR-30a-3p-CGRRF1 drives cancer chemoresistance by upregulating the KRAS/ERK pathway | PDF",1790017598,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bb723b77cf861464f3dfd303cea63731.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/041b799746b1a06e14fc728580da6b26.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/575c2e5c34358b890154a26b0855bab2.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cabecd19127d6a303680424c08e60a2a.webp",980,1306]